Views: 0 Author: Site Editor Publish Time: 2026-06-26 Origin: Site
News Release – June 26, 2026
At the China Pharmaceutical R&D Innovation Summit (PDI) held on June 26, 2026, the "2026 China Drug R&D Strength Ranking" series was officially released. Shandong Bestcomm Pharmaceutical Co., Ltd. was named to the prestigious "2026 Top 20 Chinese Pharmaceutical CRO Enterprises" list.
The ranking is jointly determined by the Summit Organizing Committee and an Expert Committee based on a comprehensive evaluation of ten key indicators: annual revenue, revenue growth, net profit, net profit growth, R&D investment, R&D investment growth, headcount, headcount growth, brand awareness, and leadership in niche segments. The selection represents a high level of excellence within China's pharmaceutical CRO/CDMO industry.
As a one-stop integrated solution provider for new drug R&D, Bestcomm has established a full-service R&D system covering active pharmaceutical ingredients (APIs), formulations, and sustained‑release/controlled‑release technologies. The company's wholly‑owned subsidiary, Shandong Loncom Pharmaceutical Co., Ltd., serves as its pilot and commercial production base, providing high‑standard cGMP‑compliant manufacturing capabilities for APIs and finished dosage forms. Together, the Group delivers end‑to‑end capabilities from R&D through to commercial supply.
Bestcomm has received numerous honors, including "National Technology Transfer Demonstration Institution," "National High‑tech Enterprise," "2018 China (Industry) Most Influential Brand," "China Technology Market Golden Bridge Award," "2019 China Pharmaceutical Industry Most Investable Enterprise," "2021 (Industry) Leading Enterprise," and "2023 (Industry) Top Ten Innovative Enterprise." It has also been consecutively selected for the "Top 20 Chinese Pharmaceutical CRO Enterprises" ranking for multiple years.
Looking ahead, Bestcomm will continue to strengthen its R&D service capabilities, leverage its technology platform expertise to help partners accelerate innovative drug development, and provide more patients with high‑quality pharmaceutical options.
